|
BMI at age 18 years, kg/m2
|
Recent BMI, kg/m2
|
Controls
|
All cases
|
luminal-like (ER+ and/or PR+)
|
|---|
|
Number
|
Number
|
OR (95% CI)
|
Number
|
OR (95% CI)
|
|---|
|
Overall
| | | | |
|
< 20.0
|
< 25.0
|
472
|
952
|
Referent
|
540
|
Referent
|
|
< 20.0
|
25.0–29.9
|
96
|
184
|
0.93 (0.70–1.24)
|
92
|
0.79 (0.56–1.13)
|
|
< 20.0
|
≥ 30.0
|
20
|
51
|
1.21 (0.69–2.13)
|
24
|
0.99 (0.50–1.96)
|
|
20.0–24.9
|
< 25.0
|
265
|
555
|
1.03 (0.85–1.25)
|
311
|
1.00 (0.79–1.26)
|
|
20.0–24.9
|
25.0–29.9
|
171
|
302
|
0.87 (0.69–1.10)
|
151
|
0.77 (0.58–1.02)
|
|
20.0–24.9
|
≥ 30.0
|
107
|
210
|
0.86 (0.65–1.13)
|
115
|
0.84 (0.60–1.17)
|
|
≥ 25.0
|
< 25.0
|
21
|
38
|
0.89 (0.50–1.58)
|
17
|
0.65 (0.32–1.35)
|
|
≥ 25.0
|
25.0–29.9
|
32
|
47
|
0.75 (0.46–1.22)
|
26
|
0.79 (0.43–1.44)
|
|
≥ 25.0
|
≥ 30.0
|
73
|
88
|
0.54 (0.38–0.78)
|
40
|
0.46 (0.29–0.73)
|
|
Restricted to studies in which cases’ ER/PR/HER2 status determined in a central laboratory
| | | | |
|
< 20.0
|
< 25.0
|
342
|
448
|
Referent
|
183
|
Referent
|
|
< 20.0
|
25.0–29.9
|
70
|
86
|
0.94 (0.66–1.35)
|
31
|
0.79 (0.49–1.29)
|
|
<20.0
|
≥ 30.0
|
16
|
21
|
1.03 (0.52–2.05)
|
6
|
0.67 (0.25–1.83)
|
|
20.0–24.9
|
< 25.0
|
186
|
253
|
1.05 (0.83–1.34)
|
103
|
1.03 (0.75–1.42)
|
|
20.0–24.9
|
25.0–29.9
|
132
|
148
|
0.86 (0.65–1.15)
|
55
|
0.75 (0.51–1.11)
|
|
20.0–24.9
|
≥ 30.0
|
81
|
89
|
0.78 (0.55–1.11)
|
37
|
0.79 (0.50–1.25)
|
|
≥ 25.0
|
< 25.0
|
15
|
23
|
1.09 (0.55–2.16)
|
8
|
0.83 (0.33–2.08)
|
|
≥ 25.0
|
25.0–29.9
|
27
|
23
|
0.68 (0.38–1.22)
|
11
|
0.76 (0.36–1.62)
|
|
≥ 25.0
|
≥ 30.0
|
58
|
41
|
0.52 (0.33–0.81)
|
15
|
0.46 (0.25–0.86)
|
|
Restricted to invasive cases
| | | | |
|
< 20.0
|
< 25.0
|
472
|
849
|
Referent
|
485
|
Referent
|
|
< 20.0
|
25.0–29.9
|
96
|
169
|
0.94 (0.70–1.26)
|
86
|
0.83 (0.58–1.20)
|
|
< 20.0
|
≥ 30.0
|
20
|
51
|
1.35 (0.77–2.38)
|
24
|
1.13 (0.56–2.28)
|
|
20.0–24.9
|
< 25.0
|
265
|
506
|
1.04 (0.85–1.27)
|
287
|
1.03 (0.81–1.32)
|
|
20.0–24.9
|
25.0–29.9
|
171
|
286
|
0.92 (0.72–1.17)
|
143
|
0.84 (0.62–1.13)
|
|
20.0–24.9
|
≥ 30.0
|
107
|
201
|
0.89 (0.67–1.18)
|
114
|
0.94 (0.67–1.34)
|
|
≥ 25.0
|
< 25.0
|
21
|
33
|
0.87 (0.48–1.59)
|
14
|
0.58 (0.27–1.26)
|
|
≥ 25.0
|
25.0–29.9
|
32
|
44
|
0.80 (0.48–1.32)
|
25
|
0.89 (0.48–1.66)
|
|
≥ 25.0
|
≥ 30.0
|
73
|
85
|
0.58 (0.40–0.84)
|
40
|
0.53 (0.33–0.85)
|
- Abbreviations: ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor-2, BMI body mass index
- aORs obtained from multivariable polychotomous unconditional logistic regression models with adjustment for source study, study site, race, education, reference age, first-degree breast cancer family history, age at menarche, number of completed pregnancies, lifetime recreational physical activity, alcohol intake, cigarette smoking status, and oral contraceptive use
